These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 16884396)

  • 1. Emerging role of a phosphatonin in mineral homeostasis and its derangements.
    Bielesz B
    Eur J Clin Invest; 2006 Aug; 36 Suppl 2():34-42. PubMed ID: 16884396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
    Stubbs J; Liu S; Quarles LD
    Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGF23 and disorders of phosphate homeostasis.
    Yu X; White KE
    Cytokine Growth Factor Rev; 2005 Apr; 16(2):221-32. PubMed ID: 15863037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
    Quarles LD
    Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging topics in pediatric bone and mineral disorders 2008.
    McKay CP; Portale A
    Semin Nephrol; 2009 Jul; 29(4):370-8. PubMed ID: 19615558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor 23 and its receptors.
    Yu X; White KE
    Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
    Imanishi Y; Kobayashi K; Kawata T; Inaba M; Nishizawa Y
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S32-7. PubMed ID: 17976083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel regulators of phosphate homeostasis and bone metabolism.
    Jüppner H
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S3-22. PubMed ID: 17976082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.
    Larsson T; Marsell R; Schipani E; Ohlsson C; Ljunggren O; Tenenhouse HS; Jüppner H; Jonsson KB
    Endocrinology; 2004 Jul; 145(7):3087-94. PubMed ID: 14988389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia.
    Xia WB; Jiang Y; Li M; Xing XP; Wang O; Hu YY; Zhang HB; Liu HC; Meng XW; Zhou XY
    Chin Med J (Engl); 2010 May; 123(9):1158-62. PubMed ID: 20529556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
    Weber TJ; Liu S; Indridason OS; Quarles LD
    J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal phosphate loss in hereditary and acquired disorders of bone mineralization.
    Bielesz B; Klaushofer K; Oberbauer R
    Bone; 2004 Dec; 35(6):1229-39. PubMed ID: 15589204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The journey from vitamin D-resistant rickets to the regulation of renal phosphate transport.
    Levine BS; Kleeman CR; Felsenfeld AJ
    Clin J Am Soc Nephrol; 2009 Nov; 4(11):1866-77. PubMed ID: 19808223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin.
    Fukumoto S; Yamashita T
    Curr Opin Nephrol Hypertens; 2002 Jul; 11(4):385-9. PubMed ID: 12105387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications.
    Damasiewicz MJ; Toussaint ND; Polkinghorne KR
    Nephrology (Carlton); 2011 Mar; 16(3):261-8. PubMed ID: 21265930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.
    Gutierrez O; Isakova T; Rhee E; Shah A; Holmes J; Collerone G; Jüppner H; Wolf M
    J Am Soc Nephrol; 2005 Jul; 16(7):2205-15. PubMed ID: 15917335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphate wasting and fibroblast growth factor-23.
    Nanes MS
    Curr Opin Endocrinol Diabetes Obes; 2013 Dec; 20(6):523-31. PubMed ID: 24157604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.
    Imel EA; Hui SL; Econs MJ
    J Bone Miner Res; 2007 Apr; 22(4):520-6. PubMed ID: 17227222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
    Sitara D; Razzaque MS; Hesse M; Yoganathan S; Taguchi T; Erben RG; Jüppner H; Lanske B
    Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.